Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical study of its novel heat shock protein 90 (Hsp90) inhibitor, STA-9090 in hematologic malignancies with a once-a-week dosing schedule. In March, Synta initiated the first Phase 1/2 clinical study of STA-9090 in hematologic malignancies with a twice-weekly dosing schedule. This is the fourth clinical study initiated on STA-9090, a synthetic, small molecule Hsp90 inhibitor with a novel chemical structure that is unrelated to the ansamycin class of Hsp90 inhibitors, including 17-AAG. The other ongoing clinical trials are once-a-week and twice-a-week dosing studies in patients with solid tumors.
“Hsp90 inhibition is one of the most exciting areas of research in oncology today because of its unique role in maintaining the function of numerous signaling proteins that are necessary for the survival and proliferation of many types of cancer cells,” said Jeffrey E. Lancet, M.D., principal investigator on the trial and Associate Member of the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute. “Based on pre-clinical data as well as early clinical data from on-going trials, we believe STA-9090 is a highly potent inhibitor of Hsp90 with the potential to be best in its class. This clinical trial will allow us to determine the optimal dose for STA-9090, to understand the signaling pathways mediated by Hsp90 inhibition within leukemic cells, and to provide additional insight on its clinical activity in refractory hematologic malignancies.”
“We are seeing encouraging signs of clinical activity as we continue dose escalation in our three ongoing trials of STA-9090, including several confirmed single agent responses, as defined by RECIST criteria, and a number of cases of prolonged stable disease,” said Vojo Vukovic, M.D., Ph.D., Senior Vice President and Chief Medical Officer, Synta. “The unique properties of STA-9090, and the collected data to date, suggest hematologic malignancies are a particularly promising opportunity for seeing signs of clinical activity. In addition, hematologic malignancies are an attractive development choice for STA-9090 because of the objective clinical markers, the high unmet need, and the opportunity for a rapid path to registration. This new trial will use results from the ongoing dose-escalating studies and preclinical experiments to begin at or near what we believe may be a therapeutically effective dose. Exploring the additional dosing schedule will provide important information on the dosing regimen for potential pivotal trials.”
"In addition to this new trial in hematologic malignancies, we expect several investigator-sponsored trials in solid tumors to be initiated in the coming months at leading cancer research institutions,” continued Dr. Vukovic. “More information about these trials will be provided as they are initiated. We anticipate presenting results related to our STA-9090 program at upcoming scientific and medical meetings."
The open-label Phase 1/2 study in patients with hematologic malignancies is designed to identify the recommended dose of STA-9090 for further study in patients with hematologic malignancies, based on a once-weekly intravenous dosing schedule, and to characterize its safety and efficacy profile in this patient population.
Study links air pollution to increased colorectal cancer risk through DNA changes